C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Evaluation Of The Safety Of Long-Term Use Of Perforomist® (formoterol Fumarate) Inhalation Solution In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD)

Subjects (N=1071; mean age, 62.6 years; 48.5% male; 89.7% white) with moderate to severe COPD (mean postbronchodilator forced expiratory volume in 1 second [FEV1 ], 44.4% of predicted value; >1 exacerbation in past 12 months) and on stable COPD therapy received nebulized Perforomist (20 ^g/2 mL twice daily; n=541) or placebo (n=530). Additionally, although the study was not designed to evaluate efficacy, fewer treatment withdrawals and larger lung function improvements were observed with Perforomist compared with placebo, when added to other maintenance COPD therapies.